0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Familial Amyloid Polyneuropathy Market Research Report 2023
Published Date: April 2023
|
Report Code: QYRE-Auto-36Z6038
Home | Market Reports | Health| Aging & Geriatrics
Global Familial Amyloid Polyneuropathy Market Insights and Forecast to 2028
BUY CHAPTERS

Global Familial Amyloid Polyneuropathy Market Research Report 2023

Code: QYRE-Auto-36Z6038
Report
April 2023
Pages:86
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Global Familial Amyloid Polyneuropathy Market

Familial amyloid polyneuropathy (FAP) or transthyretin (TTR) amyloid neuropathy are a rare group of autosomal dominant diseases caused by the deposition of protein and/or amyloid fibrils around the peripheral nerves and in various tissues, including the heart muscle.
The global Familial Amyloid Polyneuropathy market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Globally, development of new drugs for treatment of familial amyloid polyneuropathy, and rise in the prevalence of familial amyloid polyneuropathy are the prime growth drivers of familial amyloid polyneuropathy market.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Familial Amyloid Polyneuropathy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Familial Amyloid Polyneuropathy.
The Familial Amyloid Polyneuropathy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Familial Amyloid Polyneuropathy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Familial Amyloid Polyneuropathy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

Scope of Global Familial Amyloid Polyneuropathy Market Report

Report MetricDetails
Report NameGlobal Familial Amyloid Polyneuropathy Market
Base Year2022
Forecasted years2023-2029
By Company
  • Pfizer
  • GSK
  • Ionis
  • Alnylam
  • Corino Therapeutics
  • Proclara Bioscience
  • Arcturus Therapeutics
Segment by Type
  • FAP-I
  • FAP-II
  • FAP-III
  • FAP-IV
Segment by Application
  • Hospitals and Clinics
  • Others
By Region
  • North America
  • United States
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Russia
  • Nordic Countries
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia
  • Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA
Forecast unitsUSD
Report coverageRevenue and volume forecast, company share, competitive landscape, growth factors and trends
Geographic regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East & Africa

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Familial Amyloid Polyneuropathy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Familial Amyloid Polyneuropathy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 FAP-I
1.2.3 FAP-II
1.2.4 FAP-III
1.2.5 FAP-IV
1.3 Market by Application
1.3.1 Global Familial Amyloid Polyneuropathy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals and Clinics
1.3.3 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Familial Amyloid Polyneuropathy Market Perspective (2018-2029)
2.2 Familial Amyloid Polyneuropathy Growth Trends by Region
2.2.1 Global Familial Amyloid Polyneuropathy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Familial Amyloid Polyneuropathy Historic Market Size by Region (2018-2023)
2.2.3 Familial Amyloid Polyneuropathy Forecasted Market Size by Region (2024-2029)
2.3 Familial Amyloid Polyneuropathy Market Dynamics
2.3.1 Familial Amyloid Polyneuropathy Industry Trends
2.3.2 Familial Amyloid Polyneuropathy Market Drivers
2.3.3 Familial Amyloid Polyneuropathy Market Challenges
2.3.4 Familial Amyloid Polyneuropathy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Familial Amyloid Polyneuropathy Players by Revenue
3.1.1 Global Top Familial Amyloid Polyneuropathy Players by Revenue (2018-2023)
3.1.2 Global Familial Amyloid Polyneuropathy Revenue Market Share by Players (2018-2023)
3.2 Global Familial Amyloid Polyneuropathy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Familial Amyloid Polyneuropathy Revenue
3.4 Global Familial Amyloid Polyneuropathy Market Concentration Ratio
3.4.1 Global Familial Amyloid Polyneuropathy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Familial Amyloid Polyneuropathy Revenue in 2022
3.5 Familial Amyloid Polyneuropathy Key Players Head office and Area Served
3.6 Key Players Familial Amyloid Polyneuropathy Product Solution and Service
3.7 Date of Enter into Familial Amyloid Polyneuropathy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Familial Amyloid Polyneuropathy Breakdown Data by Type
4.1 Global Familial Amyloid Polyneuropathy Historic Market Size by Type (2018-2023)
4.2 Global Familial Amyloid Polyneuropathy Forecasted Market Size by Type (2024-2029)
5 Familial Amyloid Polyneuropathy Breakdown Data by Application
5.1 Global Familial Amyloid Polyneuropathy Historic Market Size by Application (2018-2023)
5.2 Global Familial Amyloid Polyneuropathy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Familial Amyloid Polyneuropathy Market Size (2018-2029)
6.2 North America Familial Amyloid Polyneuropathy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Familial Amyloid Polyneuropathy Market Size by Country (2018-2023)
6.4 North America Familial Amyloid Polyneuropathy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Familial Amyloid Polyneuropathy Market Size (2018-2029)
7.2 Europe Familial Amyloid Polyneuropathy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Familial Amyloid Polyneuropathy Market Size by Country (2018-2023)
7.4 Europe Familial Amyloid Polyneuropathy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Familial Amyloid Polyneuropathy Market Size (2018-2029)
8.2 Asia-Pacific Familial Amyloid Polyneuropathy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Familial Amyloid Polyneuropathy Market Size by Region (2018-2023)
8.4 Asia-Pacific Familial Amyloid Polyneuropathy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Familial Amyloid Polyneuropathy Market Size (2018-2029)
9.2 Latin America Familial Amyloid Polyneuropathy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Familial Amyloid Polyneuropathy Market Size by Country (2018-2023)
9.4 Latin America Familial Amyloid Polyneuropathy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Familial Amyloid Polyneuropathy Market Size (2018-2029)
10.2 Middle East & Africa Familial Amyloid Polyneuropathy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Familial Amyloid Polyneuropathy Market Size by Country (2018-2023)
10.4 Middle East & Africa Familial Amyloid Polyneuropathy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Familial Amyloid Polyneuropathy Introduction
11.1.4 Pfizer Revenue in Familial Amyloid Polyneuropathy Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 GSK
11.2.1 GSK Company Detail
11.2.2 GSK Business Overview
11.2.3 GSK Familial Amyloid Polyneuropathy Introduction
11.2.4 GSK Revenue in Familial Amyloid Polyneuropathy Business (2018-2023)
11.2.5 GSK Recent Development
11.3 Ionis
11.3.1 Ionis Company Detail
11.3.2 Ionis Business Overview
11.3.3 Ionis Familial Amyloid Polyneuropathy Introduction
11.3.4 Ionis Revenue in Familial Amyloid Polyneuropathy Business (2018-2023)
11.3.5 Ionis Recent Development
11.4 Alnylam
11.4.1 Alnylam Company Detail
11.4.2 Alnylam Business Overview
11.4.3 Alnylam Familial Amyloid Polyneuropathy Introduction
11.4.4 Alnylam Revenue in Familial Amyloid Polyneuropathy Business (2018-2023)
11.4.5 Alnylam Recent Development
11.5 Corino Therapeutics
11.5.1 Corino Therapeutics Company Detail
11.5.2 Corino Therapeutics Business Overview
11.5.3 Corino Therapeutics Familial Amyloid Polyneuropathy Introduction
11.5.4 Corino Therapeutics Revenue in Familial Amyloid Polyneuropathy Business (2018-2023)
11.5.5 Corino Therapeutics Recent Development
11.6 Proclara Bioscience
11.6.1 Proclara Bioscience Company Detail
11.6.2 Proclara Bioscience Business Overview
11.6.3 Proclara Bioscience Familial Amyloid Polyneuropathy Introduction
11.6.4 Proclara Bioscience Revenue in Familial Amyloid Polyneuropathy Business (2018-2023)
11.6.5 Proclara Bioscience Recent Development
11.7 Arcturus Therapeutics
11.7.1 Arcturus Therapeutics Company Detail
11.7.2 Arcturus Therapeutics Business Overview
11.7.3 Arcturus Therapeutics Familial Amyloid Polyneuropathy Introduction
11.7.4 Arcturus Therapeutics Revenue in Familial Amyloid Polyneuropathy Business (2018-2023)
11.7.5 Arcturus Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Familial Amyloid Polyneuropathy Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
    Table 2. Key Players of FAP-I
    Table 3. Key Players of FAP-II
    Table 4. Key Players of FAP-III
    Table 5. Key Players of FAP-IV
    Table 6. Global Familial Amyloid Polyneuropathy Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
    Table 7. Global Familial Amyloid Polyneuropathy Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 8. Global Familial Amyloid Polyneuropathy Market Size by Region (2018-2023) & (US$ Million)
    Table 9. Global Familial Amyloid Polyneuropathy Market Share by Region (2018-2023)
    Table 10. Global Familial Amyloid Polyneuropathy Forecasted Market Size by Region (2024-2029) & (US$ Million)
    Table 11. Global Familial Amyloid Polyneuropathy Market Share by Region (2024-2029)
    Table 12. Familial Amyloid Polyneuropathy Market Trends
    Table 13. Familial Amyloid Polyneuropathy Market Drivers
    Table 14. Familial Amyloid Polyneuropathy Market Challenges
    Table 15. Familial Amyloid Polyneuropathy Market Restraints
    Table 16. Global Familial Amyloid Polyneuropathy Revenue by Players (2018-2023) & (US$ Million)
    Table 17. Global Familial Amyloid Polyneuropathy Market Share by Players (2018-2023)
    Table 18. Global Top Familial Amyloid Polyneuropathy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Familial Amyloid Polyneuropathy as of 2022)
    Table 19. Ranking of Global Top Familial Amyloid Polyneuropathy Companies by Revenue (US$ Million) in 2022
    Table 20. Global 5 Largest Players Market Share by Familial Amyloid Polyneuropathy Revenue (CR5 and HHI) & (2018-2023)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Familial Amyloid Polyneuropathy Product Solution and Service
    Table 23. Date of Enter into Familial Amyloid Polyneuropathy Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Familial Amyloid Polyneuropathy Market Size by Type (2018-2023) & (US$ Million)
    Table 26. Global Familial Amyloid Polyneuropathy Revenue Market Share by Type (2018-2023)
    Table 27. Global Familial Amyloid Polyneuropathy Forecasted Market Size by Type (2024-2029) & (US$ Million)
    Table 28. Global Familial Amyloid Polyneuropathy Revenue Market Share by Type (2024-2029)
    Table 29. Global Familial Amyloid Polyneuropathy Market Size by Application (2018-2023) & (US$ Million)
    Table 30. Global Familial Amyloid Polyneuropathy Revenue Market Share by Application (2018-2023)
    Table 31. Global Familial Amyloid Polyneuropathy Forecasted Market Size by Application (2024-2029) & (US$ Million)
    Table 32. Global Familial Amyloid Polyneuropathy Revenue Market Share by Application (2024-2029)
    Table 33. North America Familial Amyloid Polyneuropathy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 34. North America Familial Amyloid Polyneuropathy Market Size by Country (2018-2023) & (US$ Million)
    Table 35. North America Familial Amyloid Polyneuropathy Market Size by Country (2024-2029) & (US$ Million)
    Table 36. Europe Familial Amyloid Polyneuropathy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 37. Europe Familial Amyloid Polyneuropathy Market Size by Country (2018-2023) & (US$ Million)
    Table 38. Europe Familial Amyloid Polyneuropathy Market Size by Country (2024-2029) & (US$ Million)
    Table 39. Asia-Pacific Familial Amyloid Polyneuropathy Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 40. Asia-Pacific Familial Amyloid Polyneuropathy Market Size by Region (2018-2023) & (US$ Million)
    Table 41. Asia-Pacific Familial Amyloid Polyneuropathy Market Size by Region (2024-2029) & (US$ Million)
    Table 42. Latin America Familial Amyloid Polyneuropathy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 43. Latin America Familial Amyloid Polyneuropathy Market Size by Country (2018-2023) & (US$ Million)
    Table 44. Latin America Familial Amyloid Polyneuropathy Market Size by Country (2024-2029) & (US$ Million)
    Table 45. Middle East & Africa Familial Amyloid Polyneuropathy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 46. Middle East & Africa Familial Amyloid Polyneuropathy Market Size by Country (2018-2023) & (US$ Million)
    Table 47. Middle East & Africa Familial Amyloid Polyneuropathy Market Size by Country (2024-2029) & (US$ Million)
    Table 48. Pfizer Company Detail
    Table 49. Pfizer Business Overview
    Table 50. Pfizer Familial Amyloid Polyneuropathy Product
    Table 51. Pfizer Revenue in Familial Amyloid Polyneuropathy Business (2018-2023) & (US$ Million)
    Table 52. Pfizer Recent Development
    Table 53. GSK Company Detail
    Table 54. GSK Business Overview
    Table 55. GSK Familial Amyloid Polyneuropathy Product
    Table 56. GSK Revenue in Familial Amyloid Polyneuropathy Business (2018-2023) & (US$ Million)
    Table 57. GSK Recent Development
    Table 58. Ionis Company Detail
    Table 59. Ionis Business Overview
    Table 60. Ionis Familial Amyloid Polyneuropathy Product
    Table 61. Ionis Revenue in Familial Amyloid Polyneuropathy Business (2018-2023) & (US$ Million)
    Table 62. Ionis Recent Development
    Table 63. Alnylam Company Detail
    Table 64. Alnylam Business Overview
    Table 65. Alnylam Familial Amyloid Polyneuropathy Product
    Table 66. Alnylam Revenue in Familial Amyloid Polyneuropathy Business (2018-2023) & (US$ Million)
    Table 67. Alnylam Recent Development
    Table 68. Corino Therapeutics Company Detail
    Table 69. Corino Therapeutics Business Overview
    Table 70. Corino Therapeutics Familial Amyloid Polyneuropathy Product
    Table 71. Corino Therapeutics Revenue in Familial Amyloid Polyneuropathy Business (2018-2023) & (US$ Million)
    Table 72. Corino Therapeutics Recent Development
    Table 73. Proclara Bioscience Company Detail
    Table 74. Proclara Bioscience Business Overview
    Table 75. Proclara Bioscience Familial Amyloid Polyneuropathy Product
    Table 76. Proclara Bioscience Revenue in Familial Amyloid Polyneuropathy Business (2018-2023) & (US$ Million)
    Table 77. Proclara Bioscience Recent Development
    Table 78. Arcturus Therapeutics Company Detail
    Table 79. Arcturus Therapeutics Business Overview
    Table 80. Arcturus Therapeutics Familial Amyloid Polyneuropathy Product
    Table 81. Arcturus Therapeutics Revenue in Familial Amyloid Polyneuropathy Business (2018-2023) & (US$ Million)
    Table 82. Arcturus Therapeutics Recent Development
    Table 83. Research Programs/Design for This Report
    Table 84. Key Data Information from Secondary Sources
    Table 85. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Familial Amyloid Polyneuropathy Market Size Comparison by Type (2023-2029) & (US$ Million)
    Figure 2. Global Familial Amyloid Polyneuropathy Market Share by Type: 2022 VS 2029
    Figure 3. FAP-I Features
    Figure 4. FAP-II Features
    Figure 5. FAP-III Features
    Figure 6. FAP-IV Features
    Figure 7. Global Familial Amyloid Polyneuropathy Market Size Comparison by Application (2023-2029) & (US$ Million)
    Figure 8. Global Familial Amyloid Polyneuropathy Market Share by Application: 2022 VS 2029
    Figure 9. Hospitals and Clinics Case Studies
    Figure 10. Others Case Studies
    Figure 11. Familial Amyloid Polyneuropathy Report Years Considered
    Figure 12. Global Familial Amyloid Polyneuropathy Market Size (US$ Million), Year-over-Year: 2018-2029
    Figure 13. Global Familial Amyloid Polyneuropathy Market Size, (US$ Million), 2018 VS 2022 VS 2029
    Figure 14. Global Familial Amyloid Polyneuropathy Market Share by Region: 2022 VS 2029
    Figure 15. Global Familial Amyloid Polyneuropathy Market Share by Players in 2022
    Figure 16. Global Top Familial Amyloid Polyneuropathy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Familial Amyloid Polyneuropathy as of 2022)
    Figure 17. The Top 10 and 5 Players Market Share by Familial Amyloid Polyneuropathy Revenue in 2022
    Figure 18. North America Familial Amyloid Polyneuropathy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 19. North America Familial Amyloid Polyneuropathy Market Share by Country (2018-2029)
    Figure 20. United States Familial Amyloid Polyneuropathy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 21. Canada Familial Amyloid Polyneuropathy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 22. Europe Familial Amyloid Polyneuropathy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 23. Europe Familial Amyloid Polyneuropathy Market Share by Country (2018-2029)
    Figure 24. Germany Familial Amyloid Polyneuropathy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 25. France Familial Amyloid Polyneuropathy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 26. U.K. Familial Amyloid Polyneuropathy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 27. Italy Familial Amyloid Polyneuropathy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 28. Russia Familial Amyloid Polyneuropathy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 29. Nordic Countries Familial Amyloid Polyneuropathy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 30. Asia-Pacific Familial Amyloid Polyneuropathy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 31. Asia-Pacific Familial Amyloid Polyneuropathy Market Share by Region (2018-2029)
    Figure 32. China Familial Amyloid Polyneuropathy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 33. Japan Familial Amyloid Polyneuropathy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 34. South Korea Familial Amyloid Polyneuropathy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 35. Southeast Asia Familial Amyloid Polyneuropathy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 36. India Familial Amyloid Polyneuropathy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 37. Australia Familial Amyloid Polyneuropathy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 38. Latin America Familial Amyloid Polyneuropathy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 39. Latin America Familial Amyloid Polyneuropathy Market Share by Country (2018-2029)
    Figure 40. Mexico Familial Amyloid Polyneuropathy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 41. Brazil Familial Amyloid Polyneuropathy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 42. Middle East & Africa Familial Amyloid Polyneuropathy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 43. Middle East & Africa Familial Amyloid Polyneuropathy Market Share by Country (2018-2029)
    Figure 44. Turkey Familial Amyloid Polyneuropathy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 45. Saudi Arabia Familial Amyloid Polyneuropathy Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 46. Pfizer Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2018-2023)
    Figure 47. GSK Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2018-2023)
    Figure 48. Ionis Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2018-2023)
    Figure 49. Alnylam Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2018-2023)
    Figure 50. Corino Therapeutics Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2018-2023)
    Figure 51. Proclara Bioscience Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2018-2023)
    Figure 52. Arcturus Therapeutics Revenue Growth Rate in Familial Amyloid Polyneuropathy Business (2018-2023)
    Figure 53. Bottom-up and Top-down Approaches for This Report
    Figure 54. Data Triangulation
    Figure 55. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS